Almirall's Seysara® Approved in China for Acne Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Businesswire
- Regulatory Approval: Almirall's Seysara® (sarecycline hydrochloride) has received approval from China's National Medical Products Administration, becoming the first oral antibiotic specifically developed for moderate to severe acne treatment, expected to launch in 2026 to meet significant patient demand.
- Clinical Efficacy: Clinical trials in the US and China have demonstrated Seysara®'s significant efficacy and favorable safety profile, effectively reducing inflammatory lesion counts and showing results as early as three weeks into treatment, thereby improving patients' quality of life.
- Market Collaboration: Almirall has entered into an exclusive commercialization agreement with Sinomune Pharmaceutical in China, ensuring rapid market entry for the new drug and enhancing the company's market share in the dermatology sector in China.
- Strategic Commitment: This approval underscores Almirall's ongoing commitment to addressing unmet medical needs in dermatology globally, aiming to leverage innovative treatments to solidify its leadership position in medical dermatology.
Analyst Views on ALM
Wall Street analysts forecast ALM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALM is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 11.100
Low
12.00
Averages
12.00
High
12.00
Current: 11.100
Low
12.00
Averages
12.00
High
12.00
About ALM
Almonty Industries Inc. is a diversified and global producer of tungsten concentrate. The Company is engaged in mining, processing and shipping tungsten concentrate from its Panasqueira Mine in Portugal. It also has a significant molybdenum resource on a separate property adjacent to the tungsten orebody at the Sangdong Mine. Its additional development projects include the Valtreixal Project in northwestern Spain and Los Santos Mine in western Spain. The Panasqueira Mine is located in Covilha, Castelo Branco, Portugal. The Sangdong Mine is located at Sangdong in the south-eastern Korean Peninsula, approximately 170 km east-southeast of Seoul, South Korea. The Valtreixal Mine is a potential open pit operation, and is located in the northwest part of the Zamora province, in the Castilla de Leon region of Spain. It also operates Woulfe, whose properties are located in Gangwon Province, Republic of Korea, and whose operations relate primarily to the development of the Sangdong Project.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.








